Benfotiamine Counteracts Smoking-induced Vascular Dysfunction In Healthy Smokers
| Effect | Increase |
| Trial Design | Double blind |
| Trial Length | 1-2 Weeks |
| Number of Subjects | 20 |
| Sex | Both Genders |
| Age Range | 18-29, 30-44 |
| Body Types | Average |
The reduction in blood flow associated with acute smoking was halved with a 3-day preload of 1050mg Benfotiamine ,with some protective effects on inflammatory markers (sVCAM) but no alterations in blood pressure or heart rate.
